CELL INTELLIGENCE · 肿瘤细胞治疗研究

基于 FAERS 数据的靶向 B 细胞成熟抗原免疫治疗中细胞因子释放综合征的信号检测与机器学习预测

Signal Detection and Machine Learning-Based Prediction of Cytokine Release Syndrome in B-Cell Maturation Antigen-Targeting Immunotherapies Using FAERS

多发性骨髓瘤中 BCMA 的生物学与治疗靶向：从配体信号到抗原逃逸

BCMA biology and therapeutic targeting in multiple myeloma: From ligand signaling to antigen escape.

CAR-T 细胞疗法在实体瘤中的挑战与局限：为何获批仅限于血液系统恶性肿瘤？

Challenges and limitations of chimeric antigen receptor T-cell therapies in solid tumors: why are approvals restricted to hematologic malignancies?

肿瘤预激 CD8⁺ 自然杀伤 T 样细胞作为复发/难治性多发性骨髓瘤的高效新型细胞疗法

Tumor-priming CD8(+) natural killer T-like cells as an efficient novel cell therapy for relapsed/refractory multiple myeloma.

TPNC 是一种通过肿瘤驱动的致敏产生的新型细胞毒性淋巴细胞产品。

复发/难治性多发性骨髓瘤临床实践中基于抗 CD38 治疗的共识指南与推荐：来自泛太平洋多发性骨髓瘤工作组

Consensus Guidelines and Recommendations for the anti-CD38-based Therapy in Clinical Practice for Relapsed/Refractory Multiple Myeloma: From the Pan-P

CAR-T 细胞治疗在 B 细胞淋巴系统恶性肿瘤患者中的当前挑战

Current Challenges in Chimeric Antigen Receptor T-cell Therapy in Patients With B-cell Lymphoid Malignancies.

利用 CAR-T 细胞疗法治疗实体瘤的新兴方法

Emerging Approaches for Solid Tumor Treatment Using CAR-T Cell Therapy.